Eptifibatide, a RGD mimetic, is a glycoprotein (GP) IIb/IIIa receptor antagonist. Clinically, the peptide is used as an antiplatelet drug in combination with heparin and aspirin in the management of unstable angina and in patients undergoing coronary angioplasty and stenting procedures.
This product is offered and sold solely for uses reasonably related to the development and submission of information under a Federal law which regulates the manufacture, use or sale of drugs (the “Bolar Exemption”). Bachem cannot be made liable for any infringement of intellectual property rights. It is the sole and only responsibility of the purchaser or user of this product to comply with the relevant national rules and regulations.
H-6654
Eptifibatide
3-Mercaptopropionyl-Homoarg-Gly-Asp-Trp-Pro-Cys-NH2
(Disulfide bond)
Acetate salt
| C35H49N11O9S2 | Mr: 831.97 | [188627-80-7] net |
| Longterm storage temperature: | -20 ± 5 °C | C35H49N11O9S2 |
Literature:
J.F.Granada and N.S.Kleiman, Am. J. Cardiovasc. Drugs, 4, 31 (2004)
M.P.Curran and G.M.Keating, Biodrugs, 20, 63 (2006)
J.F.Granada and N.S.Kleiman, Am. J. Cardiovasc. Drugs, 4, 31 (2004)
M.P.Curran and G.M.Keating, Biodrugs, 20, 63 (2006)
|
Family Description:
Bachem offers the corresponding control peptides for commonly used RGD-containing sequences:
AcDRGDS (H-3528), control AcDRLDS (H-3534)
DRGDS (H-3532), control DRLDS (H-3536)
RGDS (H-1155), control RGES (H-7745) or SDGRG (H-7740)
c(RGDfV) (H-2574), control c(RADfV) (H-4088)
GRGDSP (H-7630), control GRADSP (H-6048) or GRGESP (H-3136)
GRGDSPK (H-6190), control GRADSPK (H-5690)
GRGDS (H-1345), control GRGES (H-3166), GRDGS (H-3172), or SDGRG (H-7740)
GRGDTP (H-7725), control GRGETP (H-3752)
c(RGDfC) (H-7226), control c(RADfC) (H-7232).
Print